Application

3D-PHAD^® has been used: as a synthetic adjuvant for respiratory syncytial virus (RSV) vaccine as a synthetic adjuvant to prepare hepatitis B virus (HBV) and virus-like particles (VLP)-based human papillomavirus (HPV) vaccinesin liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice.

Biochem/physiol Actions

3-deacyl-phosphorylated hexa-acyl disaccharide (3D-PHAD^®) is derived from monophosphoryl lipid A. It is amphiphilic and associates with the virosomal membranes.

General description

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD^®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Legal Information

PHAD is a registered trademark of Avanti Polar Lipids, Inc.

3D-PHAD is a registered trademark of Avanti Polar Lipids, Inc.

Other Notes

For R&D use only. Not for drug, household, or other uses.

Packaging

2 mL Amber Glass Crimp Cap Vial (699852P-5mg)

2 mL Amber Glass Crimp Cap Vial (699852P-1mg)